• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Psoriasis study provides important insight into anti-inflammatory mechanism of TNF blockade

Article

Results from a clinical study investigating the in situ mechanism of action of etanercept (Enbrel, Amgen) in the treatment of psoriasis indicate this agent, which binds both tumor necrosis factor (TNF) and lymphotoxin, breaks the cycle of dendritic cell activation and maturation and thereby decreases T-cell activation and the production of a cascade of inflammatory mediators by multiple cell types, Alice B. Gottlieb, M.D., Ph.D., says.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.